Tideglusib (Synonyms: NP031112)

Name: Tideglusib
Brand: MedChemExpress
SKU: HY-14872
Rating: 5.0 (7 reviews)

Cat. No.: HY-14872 Pureza: 99.70%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Tideglusib (NP031112) is an irreversible GSK-3 inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β^WT (1 h preincubation) and GSK-3β^C199A (1 h preincubation), respectively.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 865854-05-3

Tamaño	Stock	Cantidad

Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	Obtener un presupuesto
500 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 7 publication(s) in Google Scholar

7 Publications Citing Use of MCE Tideglusib

•Int J Clin Exp Pathol. 2017;10(3):3033-3042.

Cell Proliferation/Viability Assay

: Tideglusib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2026 Jan 29. [Abstract]; Western blot analysis of p-GSK3β and GSK3β in BEAS-2B and MLE-12 cells treated under indicated conditions: No EF, EFs (100 mV/mm, 2 h), and EFs (100 mV/mm, 2 h)+Tideglusib (TID, 20 µM, 24 h), with quantification of p-GSK3β/GSK3β ratio.

: Tideglusib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2026 Jan 29. [Abstract]; Western blot analysis of p-GSK3β and GSK3β in BEAS-2B and MLE-12 cells treated under indicated conditions: No EF, EFs (100 mV/mm, 2 h), and EFs (100 mV/mm, 2 h)+Tideglusib (TID, 20 µM, 24 h), with quantification of p-GSK3β/GSK3β ratio.

: Tideglusib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2026 Jan 29. [Abstract]; Immunofluorescence analysis of Ki-67 in MLE-12 cells treated under indicated conditions: No EF, Tideglusib (TID; 20 µM, 24 h), EFs (100 mV/mm, 2 h), and EFs (100 mV/mm, 2 h)+Tideglusib (TID; 20 µM, 24 h), with quantification of Ki-67 positive cells.

: Tideglusib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2026 Jan 29. [Abstract]; Immunofluorescence analysis of Ki-67 in BEAS2B cells treated under indicated conditions: No EF, Tideglusib (TID; 20 μM, 24 h), EFs (100 mV/mm, 2 h), and EFs (100 mV/mm, 2 h) + TID(20 μM, 24 h), with quantification of Ki-67 positive cells.

: Tideglusib purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Oct 30:242:275-287. [Abstract]; HuH7 cells were treated with 7,8-DHF (5 μM), Tideglusib (10 μM) and concentration gradient RSL3 (0-10 μM) for 24 h. Cell viability was measured by CCK-8 assay.

: Tideglusib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2017;10(3):3033-3042.; Response of 6 HCC cell lines to 12 antitumor agents (Tideglusib; 0-10μM). The IC50 values were determined by MTS assay and calculated with the aid of GraphPad Prism 5.0 software by nonlinear regression.

: Tideglusib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2017;10(3):3033-3042.; Response of 6 HCC cell lines to 12 antitumor agents (Tideglusib; 0-10μM).

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas GSK-3:

Ver todas las isoformas

GSK-3 GSK-3α GSK-3β

Actividad biológica
Protocolo
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Tideglusib (NP031112) is an irreversible GSK-3 inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β^WT (1 h preincubation) and GSK-3β^C199A (1 h preincubation), respectively.

IC₅₀ & Target^[1]

GSK-3β(WT)

5 nM (IC₅₀)

GSK-3β(C199A)

60 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
Vero C1008	IC₅₀	0.67 3 Compound: 13	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in cell growth Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in cell growth	[PMID: 37244162]
Vero C1008	IC₅₀	0.67 3 Compound: 13	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in cell growth Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in cell growth	[PMID: 37244162]

In Vitro

Incubation of both astrocyte and microglial cultures with Tideglusib (NP031112) completely abrogates the induction of TNF-α and COX-2 expression after glutamate treatment. These effects of NP031112 are not caused by a loss of cell viability, because the 24 h exposure of astrocyte and microglial cells to this TDZD does not modify cell viability^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Injection of Tideglusib (NP031112) (50 mg/kg) into the rat hippocampus dramatically reduces kainic acid-induced inflammation, as measured by edema formation using T2-weighted magnetic resonance imaging and glial activation and has a neuroprotective effect in the damaged areas of the hippocampus^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

Peso molecular

334.39

Fòrmula

C₁₉H₁₄N₂O₂S

No. CAS

865854-05-3

Appearance

Solid

Color

White to off-white

SMILES

O=C(N(SC1=O)C2=C3C=CC=CC3=CC=C2)N1CC4=CC=CC=C4

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvente y solubilidad

In Vitro:

DMSO : 33.33 mg/mL (99.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9905 mL	14.9526 mL	29.9052 mL
5 mM	0.5981 mL	2.9905 mL	5.9810 mL
10 mM	0.2991 mL	1.4953 mL	2.9905 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.70%

Select Batch:

Ficha de datos (286 KB) SDS (396 KB)

COA (262 KB) HNMR (266 KB) RP-HPLC (222 KB) MS (70 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Domínguez JM, et al. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem, 2012, 287(2), 893-90 [Content Brief]

[2]. Luna-Medina R, et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci, 2007, 27(21), 5766-5776. [Content Brief]

Administraciòn de animales
^[2]

Rats^[2]
Adult male Wistar rats (8-12 weeks old) are used in this study. Rats (n≥5 per group) are placed into a stereotaxic apparatus. KA (1 μg in 2.5 μL PBS) alone or in combination with Tideglusib (2 ng in 2.5 μL PBS) is injected into the hippocampus. Control animals of the same age are injected with vehicle.

MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.

Referencias

[1]. Domínguez JM, et al. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem, 2012, 287(2), 893-90 [Content Brief]

[2]. Luna-Medina R, et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci, 2007, 27(21), 5766-5776. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.9905 mL	14.9526 mL	29.9052 mL	74.7630 mL
	5 mM	0.5981 mL	2.9905 mL	5.9810 mL	14.9526 mL
	10 mM	0.2991 mL	1.4953 mL	2.9905 mL	7.4763 mL
	15 mM	0.1994 mL	0.9968 mL	1.9937 mL	4.9842 mL
	20 mM	0.1495 mL	0.7476 mL	1.4953 mL	3.7381 mL
	25 mM	0.1196 mL	0.5981 mL	1.1962 mL	2.9905 mL
	30 mM	0.0997 mL	0.4984 mL	0.9968 mL	2.4921 mL
	40 mM	0.0748 mL	0.3738 mL	0.7476 mL	1.8691 mL
	50 mM	0.0598 mL	0.2991 mL	0.5981 mL	1.4953 mL
	60 mM	0.0498 mL	0.2492 mL	0.4984 mL	1.2460 mL
	80 mM	0.0374 mL	0.1869 mL	0.3738 mL	0.9345 mL

Tideglusib Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tideglusib865854-05-3NP031112NP 031112NP-031112GSK-3Glycogen synthase kinase-3Glycogen synthase kinase 3Inhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Tideglusib (Synonyms: NP031112)

Revisión del cliente

Tideglusib Related Antibodies

7 Publications Citing Use of MCE Tideglusib

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas GSK-3:

Actividad biológica

Protocolo

Pureza y Documentación

Referencias

Revisión del cliente

Tideglusib Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Tideglusib Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report